VWR Corporation (NASDAQ: VWR) and InspireMD (NASDAQ:NSPR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares VWR Corporation and InspireMD’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VWR Corporation $4.58 billion 0.95 $492.10 million $1.08 30.66
InspireMD $2.00 million 1.27 -$8.37 million N/A N/A

VWR Corporation has higher revenue and earnings than InspireMD.

Analyst Ratings

This is a summary of current ratings and target prices for VWR Corporation and InspireMD, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VWR Corporation 0 3 1 0 2.25
InspireMD 0 0 0 0 N/A

VWR Corporation presently has a consensus target price of $29.00, suggesting a potential downside of 12.41%. Given VWR Corporation’s higher probable upside, equities research analysts plainly believe VWR Corporation is more favorable than InspireMD.

Profitability

This table compares VWR Corporation and InspireMD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VWR Corporation 3.12% 15.54% 4.69%
InspireMD -449.74% -174.57% -103.04%

Summary

VWR Corporation beats InspireMD on 7 of the 8 factors compared between the two stocks.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

About InspireMD

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Receive News & Stock Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related stocks with our FREE daily email newsletter.